ABSTRACT
SARS-CoV-2 is a respiratory virus but it is also detected in a significant proportion of fecal samples of COVID-19 cases. Recent studies have shown that wastewater surveillance can be a low-cost tool for management of COVID-19 pandemic and tracking COVID-19 outbreaks in communities but most studies have been focusing on sampling from wastewater treatment plants. Institutional level of wastewater surveillance may serve well for early warning purposes since cases can be tracked and immediate action can be executed in the event of positive signal. In this study, a novel Moore swab method was developed and used for wastewater surveillance of COVID-19 at institutional level. Among the 219 swab samples tested, 28 (12.8%) swabs collected from the three campuses and two buildings were positive for SARS-CoV-2. Further individual clinical diagnosis validated the wastewater results and indicated that this method was sensitive enough to detect 1-2 cases in a building. In addition, comparison between grab and Moore swab methods from the hospital sewage line indicated that Moore swab method was more sensitive than the grab sampling method. These results suggest that the Moore swab is a sensitive, practical, and easy to use early warning tool for COVID-19 surveillance especially in low-resource settings and at an early stage of infection in communities.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Emory University Internal Funding Rollins School of Public Health (RSPH) rapid COVID-19 pilot grant
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB involves
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All our data are available upon request